See more : Parkland Corporation (PKIUF) Income Statement Analysis – Financial Results
Complete financial analysis of Hunan Warrant Pharmaceutical Co.,Ltd (688799.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hunan Warrant Pharmaceutical Co.,Ltd, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- IPE Group Limited (0929.HK) Income Statement Analysis – Financial Results
- Banco Santander, S.A. (SANTA.BR) Income Statement Analysis – Financial Results
- Bristol-Myers Squibb Company (BMY.SW) Income Statement Analysis – Financial Results
- Sunstone Hotel Investors, Inc. (SHO-PH) Income Statement Analysis – Financial Results
- Beijing Sinnet Technology Co., Ltd (300383.SZ) Income Statement Analysis – Financial Results
Hunan Warrant Pharmaceutical Co.,Ltd (688799.SS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.warrant.com.cn
About Hunan Warrant Pharmaceutical Co.,Ltd
Hunan Warrant Pharmaceutical Co., Ltd manufactures and sells pharmaceutical products. It offers medicines in the areas of immune and kidney, obstetrics and gynecology, cardiovascular, digestion, and other diseases; and anti-infection medicines. The company was founded in 2001 and is based in Changsha, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.43B | 1.29B | 1.15B | 950.63M | 824.65M | 613.25M | 374.87M | 255.63M | 246.80M | 193.57M |
| Cost of Revenue | 504.55M | 417.38M | 316.63M | 255.51M | 243.83M | 185.31M | 154.96M | 128.61M | 123.66M | 98.76M |
| Gross Profit | 928.24M | 875.28M | 829.97M | 695.12M | 580.82M | 427.94M | 219.92M | 127.03M | 123.15M | 94.81M |
| Gross Profit Ratio | 64.79% | 67.71% | 72.39% | 73.12% | 70.43% | 69.78% | 58.66% | 49.69% | 49.90% | 48.98% |
| Research & Development | 103.18M | 88.67M | 70.06M | 63.66M | 45.43M | 25.62M | 15.20M | 16.30M | 15.80M | 20.33M |
| General & Administrative | 15.91M | 9.61M | 22.90M | 13.20M | 6.90M | 5.84M | 7.64M | 34.75M | 30.52M | 31.64M |
| Selling & Marketing | 508.00M | 547.31M | 533.96M | 429.28M | 371.67M | 262.75M | 113.55M | 53.46M | 54.24M | 37.02M |
| SG&A | 577.52M | 556.92M | 556.86M | 442.48M | 378.56M | 268.59M | 121.19M | 88.21M | 84.75M | 68.65M |
| Other Expenses | 7.82M | 41.27M | 20.72M | 16.57M | 24.25M | -107.76K | 15.71M | 1.59M | 3.25M | 2.48M |
| Operating Expenses | 691.12M | 686.86M | 647.64M | 522.70M | 448.24M | 318.32M | 157.90M | 90.54M | 87.24M | 70.61M |
| Cost & Expenses | 1.20B | 1.10B | 964.28M | 778.21M | 692.07M | 503.63M | 312.86M | 219.14M | 210.89M | 169.37M |
| Interest Income | 12.44M | 7.24M | 4.16M | 855.94K | 199.12K | 175.37K | 141.85K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 120.09K | 163.17K | 166.51K | 50.95K | 12.76K | 671.07K | 2.13M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 61.02M | 49.02M | 34.28M | 29.67M | 26.19M | 23.35M | 18.80M | 34.76M | 13.98M | 6.58M |
| EBITDA | 297.36M | 248.91M | 216.54M | 194.20M | 145.89M | 122.81M | 92.68M | 53.93M | 42.22M | 29.27M |
| EBITDA Ratio | 20.75% | 18.97% | 19.42% | 21.86% | 19.26% | 21.72% | 25.76% | 21.10% | 17.11% | 13.45% |
| Operating Income | 237.11M | 196.00M | 181.89M | 160.88M | 127.73M | 104.23M | 56.03M | 19.17M | 28.24M | 19.46M |
| Operating Income Ratio | 16.55% | 15.16% | 15.86% | 16.92% | 15.49% | 17.00% | 14.95% | 7.50% | 11.44% | 10.05% |
| Total Other Income/Expenses | -7.24M | -1.04M | -1.86M | 3.60M | -73.27K | -107.76K | 15.71M | 1.59M | 3.25M | 2.48M |
| Income Before Tax | 229.88M | 194.96M | 180.03M | 164.48M | 127.65M | 104.12M | 71.74M | 20.76M | 31.49M | 21.95M |
| Income Before Tax Ratio | 16.04% | 15.08% | 15.70% | 17.30% | 15.48% | 16.98% | 19.14% | 8.12% | 12.76% | 11.34% |
| Income Tax Expense | 36.84M | 21.57M | 19.27M | 19.45M | 11.64M | 15.63M | 11.98M | 2.84M | 4.91M | 1.76M |
| Net Income | 211.32M | 182.80M | 160.76M | 145.03M | 116.01M | 88.49M | 59.76M | 18.76M | 27.88M | 20.85M |
| Net Income Ratio | 14.75% | 14.14% | 14.02% | 15.26% | 14.07% | 14.43% | 15.94% | 7.34% | 11.30% | 10.77% |
| EPS | 2.25 | 1.95 | 1.71 | 1.55 | 1.24 | 1.26 | 0.85 | 0.27 | 0.48 | 0.41 |
| EPS Diluted | 2.25 | 1.95 | 1.71 | 1.55 | 1.24 | 1.26 | 0.85 | 0.27 | 0.48 | 0.41 |
| Weighted Avg Shares Out | 93.92M | 93.80M | 93.80M | 93.80M | 93.80M | 70.23M | 70.30M | 69.48M | 58.08M | 50.85M |
| Weighted Avg Shares Out (Dil) | 93.92M | 93.80M | 93.80M | 93.80M | 93.80M | 70.23M | 70.30M | 69.48M | 58.08M | 50.85M |
Source: https://incomestatements.info
Category: Stock Reports